Liệu pháp proton cho ung thư tế bào gan có xâm lấn đường mật

Park J, Kim HC, Lee JH, Cho EJ, Kim M, Hur S, et al. Chemoembolisation for hepatocellular carcinoma with bile duct invasion: is preprocedural biliary drainage mandatory? Eur Radiol. 2018;28:1540–50. Ikenaga N, Chijiiwa K, Otani K, Ohuchida J, Uchiyama S, Kondo K. Clinicopathologic characteristics of hepatocellular carcinoma with bile duct invasion. J Gastrointest Surg. 2009;13:492–7. Oba A, Takahashi S, Kato Y, Gotohda N, Kinoshita T, Shibasaki H, et al. Usefulness of resection for hepatocellular carcinoma with macroscopic bile duct tumor thrombus. Anticancer Res. 2014;34:4367–72. Meng KW, Dong M, Zhang WG, Huang QX. Clinical characteristics and surgical prognosis of hepatocellular carcinoma with bile duct invasion. Gastroenterol Res Pract. 2014;2014:604971. Yang X, Qiu Z, Ran R, Cui L, Luo X, Wu M, et al. Prognostic importance of bile duct invasion in surgical resection with curative intent for hepatocellular carcinoma using PSM analysis. Oncol Lett. 2018;16:3593–602. Wakamatsu T, Ogasawara S, Chiba T, Yokoyama M, Inoue M, Kanogawa N, et al. Impact of radiofrequency ablation-induced glisson’s capsule-associated complications in patients with hepatocellular carcinoma. PLoS ONE. 2017;12:1–14. Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Nakashima Y, Ikeno H, et al. Main bile duct stricture occurring after transcatheter arterial chemoembolization for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33:1168–79. Bortfeld T, Schlegel W. Physics in Medicine & Biology Related content An analytical approximation of depth - dose distributions for therapeutic proton beams for therapeutic proton beams, 1996. Lawrence JH. Alpha and Proton Heavy particles and the. Trans Am Clin Clim Assoc. 1964;75:111–6. Iizumi T, Okumura T, Sekino Y, Takahashi H, Tsai YL, Takizawa D, et al. Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma. J Radiat Res. 2021;62:682–7. Sugahara S, Oshiro Y, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al. Proton Beam Therapy for large Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2010;76:460–6. Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol. 2005;23:1839–46. Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009;74:831–6. Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, et al. Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys. 2011;81:1039–45. Fukuda K, Okumura T, Abei M, Fukumitsu N, Ishige K, Mizumoto M, et al. Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer Sci. 2017;108:497–503. Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, et al. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlentherapie und Onkol. 2009;185:782–8. Sekino Y, Okumura T, Fukumitsu N, Iizumi T, Numajiri H. Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. J Cancer Res Clin Oncol. 2020;146:711–20. Fukumitsu N, Ishida M, Terunuma T, Mizumoto M, Hashimoto T, Moritake T, et al. Reproducibility of image quality for moving objects using respiratory-gated computed tomography: a study using a phantom model. J Radiat Res. 2012;53:945–53. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7. Takahashi H, Sekino Y, Mori K, Okumura T, Nasu K, Fukuda K, et al. Indicator for local recurrence of hepatocellular carcinoma after proton beam therapy: analysis of attenuation difference between the irradiated tumor and liver parenchyma on contrast enhancement CT. Br J Radiol. 2020;93:20190375. Zeng H, Xu LB, Wen JM, Zhang R, Zhu MS, Shi X, De, et al. Hepatocellular carcinoma with bile duct tumor thrombus: a clinicopathological analysis of factors predictive of recurrence and outcome after surgery. Med (United States). 2015;94:e364. Jang Y-R, Lee K-W, Kim H, Lee J-M, Yi N-J, Suh K-S. Bile duct invasion can be an independent prognostic factor in early stage hepatocellular carcinoma. Korean J hepato-biliary-pancreatic Surg. 2015;19:167–72. Qin LX, Ma ZC, Wu ZQ, Fan J, Zhou X, Da, Sun HC, et al. Diagnosis and surgical treatments of hepatocellular carcinoma with tumor thrombosis in bile duct: experience of 34 patients. World J Gastroenterol. 2004;10:1397–401. Wang C, Yang Y, Sun D, Jiang Y. Prognosis of hepatocellular carcinoma patients with bile duct tumor thrombus after hepatic resection or liver transplantation in asian populations: a meta-analysis. PLoS ONE. 2017;12:1–10. Qin LX, Tang ZY. Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis. World J Gastroenterol. 2003;9:385–91. Oshiro Y, Mizumoto M, Okumura T, Fukuda K, Fukumitsu N, Abei M, et al. Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma. Radiother Oncol. 2017;123:240–5. Murakami M, Fukumitsu N, Okumura T, Numajiri H, Murofushi K, Ohnishi K, et al. Three cases of hepatocellular carcinoma treated 4 times with proton beams. Mol Clin Oncol. 2020;12:31–5. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909–22. Lin MX, Ye JY, Tian WS, Xu M, Zhuang BW, Lu M, De, et al. Risk factors for bile Duct Injury after Percutaneous Thermal ablation of malignant liver tumors: a retrospective case–control study. Dig Dis Sci. 2017;62:1086–94. Shibata T, Yamamoto Y, Yamamoto N, Maetani Y, Shibata T, Ikai I, et al. Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J Vasc Interv Radiol. 2003;14:1535–42. Oshima S, Tani N, Takaishi K, Hirano M, Makari Y, Hoshi M, et al. [Clinical evaluation of the risk factors for liver abscess after TACE or RFA]. Gan To Kagaku Ryoho. 2014;41:2113–5. Kobayashi S, Nakanuma Y, Terada T, Matsui O. Postmortem survey of bile duct necrosis and biloma in hepatocellular carcinoma after transcatheter arterial chemoembolization therapy: relevance to microvascular damages of peribiliary capillary plexus. Am J Gastroenterol. 1993;88:1410–5. Clark TWI. Complications of hepatic chemoembolization. Semin Intervent Radiol. 2006;23:119–25. Dhamija E, Paul SB, Gamanagatti SR, Acharya SK. Biliary complications of arterial chemoembolization of hepatocellular carcinoma. Diagn Interv Imaging. 2015;96:1169–75. Wu J-Y, Huang L-M, Bai Y-N, Wu J-Y, Wei Y-G, Zhang Z-B, et al. Imaging features of Hepatocellular Carcinoma with bile Duct Tumor Thrombus: a Multicenter Study. Front Oncol. 2021;11:723455.